Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Liabilities: 2019-2025

Historic Total Liabilities for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $150.2 million.

  • Nurix Therapeutics' Total Liabilities rose 9.85% to $150.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $150.2 million, marking a year-over-year increase of 9.85%. This contributed to the annual value of $142.3 million for FY2024, which is 8.22% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Total Liabilities of $150.2 million as of Q3 2025, which was up 4.35% from $144.0 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Total Liabilities ranged from a high of $155.1 million in Q4 2023 and a low of $74.4 million during Q3 2023.
  • Over the past 3 years, Nurix Therapeutics' median Total Liabilities value was $140.3 million (recorded in 2024), while the average stood at $128.0 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Total Liabilities slumped by 36.32% in 2023, and later spiked by 83.85% in 2024.
  • Nurix Therapeutics' Total Liabilities (Quarterly) stood at $134.5 million in 2021, then dropped by 15.92% to $113.1 million in 2022, then soared by 37.18% to $155.1 million in 2023, then declined by 8.22% to $142.3 million in 2024, then increased by 9.85% to $150.2 million in 2025.
  • Its Total Liabilities stands at $150.2 million for Q3 2025, versus $144.0 million for Q2 2025 and $134.1 million for Q1 2025.